STOCKHOLM - Continuous ruxolitinib therapy extends survival over that seen with best available therapy (BAT) in patients with myelofibrosis and also provides durable reductions in splenomegaly, according to results released at the 18th Congress of the European Hematology Association (EHA)... via Featured Health News from Medical News Today Read More Here..
Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/06/ruxolitinib-boosts-survival-in-patients_29.html
No comments:
Post a Comment